stoxline Quote Chart Rank Option Currency Glossary
  
RetinalGenix Technologies Inc. (RTGN)
3.1  0.01 (0.32%)    01-10 10:41
Open: 3.1
High: 3.1
Volume: 100
  
Pre. Close: 3.09
Low: 3.1
Market Cap: 55(M)
Technical analysis
2023-11-17 4:53:13 PM
Short term     
Mid term     
Targets 6-month :  35.98 1-year :  36.76
Resists First :  30.8 Second :  31.47
Pivot price 30.76
Supports First :  29.71 Second :  24.72
MAs MA(5) :  30.33 MA(20) :  30.75
MA(100) :  30.92 MA(250) :  0
MACD MACD :  -0.2 Signal :  -0.1
%K %D K(14,3) :  0 D(3) :  0
RSI RSI(14): 44.1
52-week High :  32.02 Low :  27.86
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ TGN ] has closed above bottom band by 27.4%. Bollinger Bands are 27.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 30.41 - 30.56 30.56 - 30.68
Low: 29.91 - 30.12 30.12 - 30.29
Close: 30.05 - 30.36 30.36 - 30.61
Company Description

RetinalGeniX Technologies, Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ocular, optical, and sight-threatening disorders. Its products include the RetinalGeniX Imaging System, a diabetic non-mydriatic mass retinal imaging and screening device; and RetinalCam, a real-time in-home retinal monitoring, imaging, and physician alert system. The company was incorporated in 2017 and is headquartered in Petaluma, California. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.

Headline News

Thu, 22 Feb 2024
RetinalGeniX™ Technologies Inc. Granted a Patent for System And Method For Visualization Of Ocular Anatomy - Yahoo Finance

Tue, 26 Dec 2023
RetinalGeniX™ Technologies Inc. Contracts With MEDsan, Inc. to Provide Diagnostic Testing Services for Its ... - GlobeNewswire

Thu, 21 Dec 2023
RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Company's Medical Advisory Board - Yahoo Finance

Thu, 09 Nov 2023
RetinalGeniX™ Technologies Inc. Announces the Submission of Two Provisional Patent Applications For ... - GlobeNewswire

Wed, 08 Nov 2023
RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug ... - Yahoo Finance

Wed, 07 Jun 2023
Retinalgenix Technologies, Inc. Expands Team to Hasten the Launch of DNA/GPS - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
OTC
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 0 (M)
Shares Float 0 (M)
Held by Insiders 0 (%)
Held by Institutions 0 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) 0 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android